ELDN
Eledon Pharmaceuticals, Inc. NASDAQ Listed Sep 17, 2014$3.92
+5.95%
vs $3.70
Mkt Cap $320.8M
52w Low $1.39
85.2% of range
52w High $4.36
50d MA $3.66
200d MA $2.73
P/E (TTM)
-7.0x
EV/EBITDA
—
P/B
2.4x
Debt/Equity
0.0x
ROE
-56.3%
P/FCF
-5.1x
RSI (14)
53.30
ATR (14)
$0.22
Beta
0.84
50d MA
$3.66
200d MA
$2.73
Avg Volume
1.1M
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
19900 MacArthur Boulevard · Irvine, CA 92612 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.20 | -0.10 | +50.0% | 2.85 | +0.7% | +1.1% | +7.6% | -6.8% | +1.0% | +1.4% | — |
| Nov 14, 2025 | AMC | -0.22 | -0.21 | +4.5% | 1.76 | +2.3% | -8.0% | -4.9% | +0.6% | -10.3% | +3.6% | — |
| Aug 14, 2025 | AMC | -0.23 | -0.13 | +43.5% | 2.60 | +1.2% | +1.2% | -1.1% | +0.8% | -1.5% | -0.8% | — |
| May 14, 2025 | AMC | -0.28 | -0.08 | +71.4% | 2.83 | +0.4% | +2.1% | -0.7% | +5.9% | +0.7% | +2.9% | — |
| Mar 20, 2025 | AMC | -0.32 | -0.64 | -100.0% | 3.44 | -2.0% | +2.0% | +2.8% | -3.9% | -2.9% | +1.2% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.32 | -6.7% | 4.82 | -2.3% | -11.4% | -3.3% | -3.1% | -2.5% | -0.5% | — |
| Aug 19, 2024 | AMC | -0.31 | -0.32 | -3.2% | 2.76 | +2.2% | +3.3% | +0.7% | +2.8% | -1.7% | +0.0% | — |
| May 9, 2024 | AMC | -0.37 | -0.34 | +8.1% | 2.40 | +1.2% | -3.8% | -5.2% | +6.8% | +7.3% | +11.6% | — |
| Mar 28, 2024 | AMC | -0.38 | -0.29 | +23.7% | 2.06 | +1.9% | -3.4% | -3.0% | -12.4% | +4.1% | -2.3% | — |
| Nov 9, 2023 | AMC | -0.41 | -0.35 | +14.6% | 1.15 | +1.7% | +0.9% | +3.4% | +4.2% | +0.0% | +0.0% | — |
| Aug 10, 2023 | AMC | -0.47 | -0.40 | +14.9% | 1.23 | +0.0% | +0.0% | -1.6% | +2.5% | -4.8% | +9.3% | — |
| May 11, 2023 | AMC | -0.71 | -0.75 | -5.6% | 2.77 | -4.3% | -13.0% | -3.7% | -4.7% | +1.8% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $1.62 | $1.61 | -0.6% | -4.9% | +0.6% | -10.3% | +3.6% | +11.8% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.59 | $2.59 | +0.0% | -1.5% | +1.6% | +0.8% | +3.8% | -4.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.88 | $3.90 | +0.5% | -0.8% | +5.7% | -1.5% | +0.0% | +6.0% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.81 | +0.4% | +2.5% | -1.0% | -4.2% | +2.2% | +3.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $2.43 | +1.2% | -3.8% | -5.2% | +6.8% | +7.3% | +11.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.15 | -11.9% | -7.4% | +8.0% | -1.6% | -3.8% | -5.2% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.88 | $2.07 | +10.1% | +6.9% | +3.0% | +2.4% | +0.5% | -3.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.16 | $1.16 | +0.0% | +3.4% | +4.2% | +0.0% | +0.0% | +1.6% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.42 | +6.8% | +0.8% | +6.7% | +4.2% | +7.0% | -0.9% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.32 | $1.39 | +5.3% | +11.4% | -0.7% | +13.7% | -3.0% | -3.7% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.89 | $1.89 | +0.0% | -2.1% | -5.4% | +20.0% | -6.2% | -2.0% |
| Jun 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.19 | $3.19 | +0.0% | +1.3% | +4.0% | -2.7% | -6.4% | +5.2% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.09 | $5.03 | -1.2% | +2.0% | -0.2% | -2.5% | -3.2% | -3.3% |
| Apr 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $11.48 | $10.90 | -5.1% | -7.4% | -3.2% | -3.2% | +0.4% | -0.9% |
| Mar 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.65 | $14.45 | +5.9% | -3.2% | -7.9% | -4.0% | -9.7% | -2.4% |
| Feb 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $14.99 | $16.99 | +13.3% | +15.5% | +10.7% | +0.1% | -1.2% | -2.5% |
No insider trades available.
8-K · 2.02
!! High
Eledon Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Eledon's advancement of tegoprubart across multiple transplant indications suggests potential for significant market expansion if clinical efficacy is demonstrated, justifying investor attention to upcoming trial results.
Mar 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Defilade Capital Management, L.p. | 3,564,127 | $11M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 3,293,134 | $10M | New | Mar 2026 |
| 3 | Ensign Peak Advisors, Inc | 2,464,919 | $8M | — | Mar 2026 |
| 4 | Blue Owl Capital Holdings Lp | 1,419,912 | $4M | Reduced | Mar 2026 |
| 5 | Adar1 Capital Management, Llc | 974,421 | $3M | New | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 869,544 | $3M | Added | Mar 2026 |
| 7 | Sg Americas Securities, Llc | 635,845 | $2M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 547,447 | $2M | Reduced | Mar 2026 |
| 9 | Northern Trust Corp | 543,842 | $2M | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 429,889 | $1M | New | Mar 2026 |
| 11 | Cm Management, Llc | 650,000 | $982K | Added | Dec 2025 |
| 12 | 22nw, Lp | 636,364 | $961K | — | Dec 2025 |
| 13 | Jane Street Group, Llc | 489,376 | $739K | Added | Dec 2025 |
| 14 | Morgan Stanley | 481,090 | $726K | Added | Dec 2025 |
| 15 | Aqr Capital Management Llc | 172,417 | $531K | Added | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 144,148 | $444K | Added | Mar 2026 |
| 17 | Bit Capital Gmbh | 134,000 | $413K | New | Mar 2026 |
| 18 | Susquehanna International Group, Llp | 109,949 | $339K | Added | Mar 2026 |
| 19 | Daytona Street Capital Llc | 81,166 | $254K | Added | Mar 2026 |
| 20 | Nuveen, Llc | 76,292 | $235K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$320.8M
Enterprise Value
$187.5M
P/E (TTM)
-7.00x
Forward P/E
—
PEG Ratio
0.11x
P/B
2.35x
P/S
—
P/FCF
-5.15x
EV/EBITDA
—
Shares Out
81.8M
Financials (TTM)
Revenue
$0
Net Income
-$45.6M
EBITDA
-$83.3M
Free Cash Flow
-$62.3M
Op Cash Flow
-$62.3M
EPS Basic
$-0.56
EPS Diluted
$-0.56
EPS Forward
$-0.87
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$237.6M
Total Liab.
$100.8M
Total Equity
$136.8M
Cash
$133.3M
LT Debt
$0
Book Value/Sh
$1.67
Debt/Equity
0.00x
Current Ratio
7.40
Quick Ratio
7.40
Returns & Growth
ROE
-56.3%
ROA
-27.0%
ROIC
-37.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+25.3%
Price Returns
2W
-3.5%
1M
+4.7%
3M
+45.4%
6M
+133.7%
12M
+27.0%
Technicals
52W High
$4.36
52W Low
$1.39
50d MA
$3.66
200d MA
$2.73
RSI (14)
53.30
ATR (14)
$0.22
Beta
0.84
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.00
High
$5.00
Low
$5.00
Median
$5.00
Data updated apr 25, 2026 6:50am
· Source: financialmodelingprep.com